Physician profile

Kyle David Moran

Family Medicine · Pearisburg, VA

NPI 1942874185

$253.10

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$115.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $75.18 2022-2024 Rybelsus, Ozempic
Abbvie INC. $39.85 2023
Nestle Healthcare Nutrition INC. $37.30 2021
Sun Pharmaceutical Industries INC. $30.98 2024
Organon LLC $24.99 2022
Csl Behring $16.46 2022
Exact Sciences Corporation $15.23 2024 Cologuard Collection Kit
Astrazeneca Pharmaceuticals LP $13.11 2023 Lokelma

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kyle David Moran

$253.10

in general payments reported 2019-2025

Years
2021-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/11301464/kyle-david-moran

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.